These Juno investors will cash out big in Celgene's $9 billion takeover

January 23, 2018

Juno Therapeutics Inc.’s top investors will cash out stock worth hundreds of millions of dollars in the biotech company’s pending acquisition by Celgene Corp.

Celgene’s $9 billion takeover of Seattle-based Juno is priced at $87 per share.

Summit, New Jersey-based Celgene already owns $900.5 million worth of Juno stock.

Celgene bought about $850 million worth of Juno stock (at $93 per share) in 2015 and paid Juno $150 million in cash for options to develop and commercialize Juno’s immunotherapy…

Seattle Biz Journal
These Juno investors will cash out big in Celgene's billion takeover

Comments are closed.

Shrimp Tank © 2018